Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 170325, 16 pages
http://dx.doi.org/10.1155/2012/170325
Review Article

New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy

Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada T6G 1Z2

Received 24 February 2012; Accepted 17 April 2012

Academic Editor: Lisa Wiesmuller

Copyright © 2012 Razmik Mirzayans et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Zhang, P. Brazhnik, and J. J. Tyson, “Exploring mechanisms of the DNA-damage response: p53 pulses and their possible relevance to apoptosis,” Cell Cycle, vol. 6, no. 1, pp. 85–94, 2007. View at Google Scholar · View at Scopus
  2. N. Desilet, T. N. Campbell, and F. Y. M. Choy, “p53-based anti-cancer therapies: an empty promise?” Current Issues in Molecular Biology, vol. 12, no. 3, pp. 143–146, 2010. View at Google Scholar · View at Scopus
  3. T. Enoch and C. Norbury, “Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM,” Trends in Biochemical Sciences, vol. 20, no. 10, pp. 426–430, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. M. S. Meyn, “Ataxia-telangiectasia and cellular responses to DNA damage,” Cancer Research, vol. 55, no. 24, pp. 5991–6001, 1995. View at Google Scholar · View at Scopus
  5. I. B. Roninson, E. V. Broude, and B. D. Chang, “If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells,” Drug Resistance Updates, vol. 4, no. 5, pp. 303–313, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. I. B. Roninson, “Tumor cell senescence in cancer treatment,” Cancer Research, vol. 63, no. 11, pp. 2705–2715, 2003. View at Google Scholar · View at Scopus
  7. Z. Han, W. Wei, S. Dunaway et al., “Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin,” Journal of Biological Chemistry, vol. 277, no. 19, pp. 17154–17160, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Castedo, J. L. Perfettini, T. Roumier, K. Andreau, R. Medema, and G. Kroemer, “Cell death by mitotic catastrophe: a molecular definition,” Oncogene, vol. 23, no. 16, pp. 2825–2837, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Sohn, F. Essmann, K. Schulze-Osthoff, and R. U. Jänicke, “p21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation,” Cancer Research, vol. 66, no. 23, pp. 11254–11262, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Afshar, N. Jelluma, X. Yang et al., “Radiation-induced caspase-8 mediates p53-independent apoptosis in glioma cells,” Cancer Research, vol. 66, no. 8, pp. 4223–4232, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. D. A. Gewirtz, S. E. Holt, and L. W. Elmore, “Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation,” Biochemical Pharmacology, vol. 76, no. 8, pp. 947–957, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Sliwinska, G. Mosieniak, K. Wolanin et al., “Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells,” Mechanisms of Ageing and Development, vol. 130, no. 1-2, pp. 24–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Mansilla, M. Bataller, and J. Portugal, “A nuclear budding mechanism in transiently arrested cells generates drug-sensitive and drug-resistant cells,” Biochemical Pharmacology, vol. 78, no. 2, pp. 123–132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. R. D. C. Barley, L. Enns, M. C. Paterson, and R. Mirzayans, “Aberrant p21WAF1-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li-Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations,” Oncogene, vol. 17, no. 5, pp. 533–543, 1998. View at Google Scholar · View at Scopus
  15. R. Mirzayans, A. Scott, M. Cameron, and D. Murray, “Induction of accelerated senescence by γ radiation in human solid tumor-derived cell lines expressing wild-type TP53,” Radiation Research, vol. 163, no. 1, pp. 53–62, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Mirzayans and D. Murray, “Cellular senescence: implications for cancer therapy,” in Monograph, R. B. Garvey, Ed., pp. 1–130, Nova Science Publishers, Hauppauge, NY, USA, 2009. View at Google Scholar
  17. R. Mirzayans, A. Scott, B. Andrais, S. Pollock, and D. Murray, “Ultraviolet light exposure triggers nuclear accumulation of p21WAF1 and accelerated senescence in human normal and nucleotide excision repair-deficient fibroblast strains,” Journal of Cellular Physiology, vol. 215, no. 1, pp. 55–67, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Mirzayans, B. Andrais, A. Scott, M. C. Paterson, and D. Murray, “Single-cell analysis of p16INK4a and p21WAF1 expression suggests distinct mechanisms of senescence in normal human and Li-Fraumeni syndrome fibroblasts,” Journal of Cellular Physiology, vol. 223, no. 1, pp. 57–67, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Cho, S. Gorina, P. D. Jeffrey, and N. P. Pavletich, “Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations,” Science, vol. 265, no. 5170, pp. 346–355, 1994. View at Google Scholar · View at Scopus
  20. B. P. Bouchet, C. C. de Fromentel, A. Puisieux, and C. M. Galmarini, “p53 as a target for anti-cancer drug development,” Critical Reviews in Oncology/Hematology, vol. 58, no. 3, pp. 190–207, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. M. F. Lavin and N. Gueven, “The complexity of p53 stabilization and activation,” Cell Death and Differentiation, vol. 13, no. 6, pp. 941–950, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. R. S. Akhtar, Y. Geng, B. J. Klocke et al., “BH3-only proapoptotic Bcl-2 family members Noxa and Puma mediate neural precursor cell death,” The Journal of Neuroscience, vol. 26, no. 27, pp. 7257–7264, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Pietrzak and M. Puzianowska-Kuznicka, “p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter,” Biological Chemistry, vol. 389, no. 4, pp. 383–393, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. W. H. Hoffman, S. Biade, J. T. Zilfou, J. Chen, and M. Murphy, “Transcriptional repression of the anti-apoptotic survivin gene by wild type p53,” Journal of Biological Chemistry, vol. 277, no. 5, pp. 3247–3257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. K. V. Chin, K. Ueda, I. Pastan, and M. M. Gottesman, “Modulation of activity of the promoter of the human MDR1 gene by Ras and p53,” Science, vol. 255, no. 5043, pp. 459–462, 1992. View at Google Scholar · View at Scopus
  26. R. A. Johnson, E. M. Shepard, and K. W. Scotto, “Differential regulation of MDR1 transcription by the p53 family members: role of the DNA binding domain,” Journal of Biological Chemistry, vol. 280, no. 14, pp. 13213–13219, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Löhr, C. Möritz, A. Contente, and M. Dobbelstein, “p21/CDKN1A mediates negative regulation of transcription by p53,” Journal of Biological Chemistry, vol. 278, no. 35, pp. 32507–32516, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Michael and M. Oren, “The p53-Mdm2 module and the ubiquitin system,” Seminars in Cancer Biology, vol. 13, no. 1, pp. 49–58, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Ljungman, “Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress,” Neoplasia, vol. 2, no. 3, pp. 208–225, 2000. View at Google Scholar · View at Scopus
  30. D. W. Meek, “The p53 response to DNA damage,” DNA Repair, vol. 3, no. 8-9, pp. 1049–1056, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Ling and W. G. Zuo Zhu, “p53: structure, function and therapeutic applications,” Journal of Cancer Molecules, vol. 2, pp. 141–153, 2006. View at Google Scholar
  32. K. H. Vousden and C. Prives, “Blinded by the light: the growing complexity of p53,” Cell, vol. 137, no. 3, pp. 413–431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Enns, R. D. C. Barley, M. C. Paterson, and R. Mirzayans, “Radiosensitivity in ataxia telangiectasia fibroblasts is not associated with deregulated apoptosis,” Radiation Research, vol. 150, no. 1, pp. 11–16, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Mirzayans and D. Murray, “Role of the ataxia telangiectasia mutated protein in stress-induced premature senescence,” in Ataxia: Causes, Symptoms and Treatment, S. H. Hong, Ed., pp. 1–34, Nova Science, Hauppauge, NY, USA, 2012. View at Google Scholar
  35. J. W. Harper, G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge, “The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin- dependent kinases,” Cell, vol. 75, no. 4, pp. 805–816, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Xiong, G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach, “p21 is a universal inhibitor of cyclin kinases,” Nature, vol. 366, no. 6456, pp. 701–704, 1993. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Rousseau, D. Cannella, J. Boulaire, P. Fitzgerald, A. Fotedar, and R. Fotedar, “Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway,” Oncogene, vol. 18, no. 30, pp. 4313–4325, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. E. V. Broude, M. E. Swift, C. Vivo et al., “p21Waf1/Cip1/Sdi1 mediates retinoblastoma protein degradation,” Oncogene, vol. 26, no. 48, pp. 6954–6958, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Bunz, A. Dutriaux, C. Lengauer et al., “Requirement for p53 and p21 to sustain G2 arrest after DNA damage,” Science, vol. 282, no. 5393, pp. 1497–1501, 1998. View at Google Scholar · View at Scopus
  40. L. D. Gillis, A. M. Leidal, R. Hill, and P. W. K. Lee, “p21Cip1/WAF1 mediates cyclin B1 degradation in response to DNA damage,” Cell Cycle, vol. 8, no. 2, pp. 253–256, 2009. View at Google Scholar · View at Scopus
  41. L. S. H. Chuang, H. I. Ian, T. W. Koh, H. H. Ng, G. Xu, and B. F. L. Li, “Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1,” Science, vol. 277, no. 5334, pp. 1996–2000, 1997. View at Publisher · View at Google Scholar · View at Scopus
  42. S. B. Baylin, “Tying it all together: epigenetics, genetics, cell cycle, and cancer,” Science, vol. 277, no. 5334, pp. 1948–1949, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. B. D. Chang, K. Watanabe, E. V. Broude et al., “Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 8, pp. 4291–4296, 2000. View at Google Scholar · View at Scopus
  44. L. Delavaine and N. B. La Thangue, “Control of E2F activity by p21Waf1/Cip1,” Oncogene, vol. 18, no. 39, pp. 5381–5392, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Kitaura, M. Shinshi, Y. Uchikoshi et al., “Reciprocal regulation via protein-protein interaction between c-Myc and p21cip1/waf1/sdi1 in DNA replication and transcription,” Journal of Biological Chemistry, vol. 275, no. 14, pp. 10477–10483, 2000. View at Publisher · View at Google Scholar
  46. V. Devgan, C. Mammucari, S. E. Millar, C. Brisken, and G. P. Dotto, “p21Waf1/Cip1 is a negative transcriptional regulator of Wnt4 expression downstream of Notch1 activation,” Genes and Development, vol. 19, no. 12, pp. 1485–1495, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. W. S. El-Deiry, T. Tokino, V. E. Velculescu et al., “WAF1, a potential mediator of p53 tumor suppression,” Cell, vol. 75, no. 4, pp. 817–825, 1993. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Noda, Y. Ning, S. F. Venable, O. M. Pereira-Smith, and J. R. Smith, “Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen,” Experimental Cell Research, vol. 211, no. 1, pp. 90–98, 1994. View at Publisher · View at Google Scholar · View at Scopus
  49. J. W. Shay, “At the end of the millennium, a view of the end,” Nature Genetics, vol. 23, no. 4, pp. 382–383, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. Q. M. Chen, K. R. Prowse, V. C. Tu, S. Purdom, and M. H. K. Linskens, “Uncoupling the senescent phenotype from telomere shortening in hydrogen peroxide-treated fibroblasts,” Experimental Cell Research, vol. 265, no. 2, pp. 294–303, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. J. W. Shay and I. B. Roninson, “Hallmarks of senescence in carcinogenesis and cancer therapy,” Oncogene, vol. 23, no. 16, pp. 2919–2933, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. U. Herbig, W. A. Jobling, B. P. C. Chen, D. J. Chen, and J. M. Sedivy, “Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21CIP1, but not p16INK4a,” Molecular Cell, vol. 14, no. 4, pp. 501–513, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. D. A. Freedman and J. Folkman, “CDK2 translational down-regulation during endothelial senescence,” Experimental Cell Research, vol. 307, no. 1, pp. 118–130, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Crescenzi, G. Palumbo, J. De Boer, and H. J. M. Brady, “Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy,” Clinical Cancer Research, vol. 14, no. 6, pp. 1877–1887, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. B. P. Zhou, Y. Liao, W. Xia, B. Spohn, M. H. Lee, and M. C. Hung, “Cytoplasmic localization of p21CIP1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells,” Nature Cell Biology, vol. 3, no. 3, pp. 245–252, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. B. P. Zhou and M. C. Hung, “Novel targets of Akt, p21Cip1/WAF1, and MDM2,” Seminars in Oncology, vol. 29, no. 3, pp. 62–70, 2002. View at Google Scholar · View at Scopus
  57. B. P. Zhou and M. C. Hung, “Dysregulation of cellular signaling by HER2/neu in breast cancer,” Seminars in Oncology, vol. 30, no. 5, pp. 38–48, 2003. View at Google Scholar · View at Scopus
  58. A. Suzuki, Y. Tsutomi, N. Yamamoto, T. Shibutani, and K. Akahane, “Mitochondrial regulation of cell death: mitochondria are essential for procaspase 3-p21 complex formation to resist Fas-mediated cell death,” Molecular and Cellular Biology, vol. 19, no. 5, pp. 3842–3847, 1999. View at Google Scholar · View at Scopus
  59. D. Sohn, F. Essmann, K. Schulze-Osthoff, and R. U. Jänicke, “p21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation,” Cancer Research, vol. 66, no. 23, pp. 11254–11262, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. H. V. Le, A. J. Minn, and J. Massagué, “Cyclin-dependent kinase inhibitors uncouple cell cycle progression from mitochondrial apoptotic functions in DNA-damaged cancer cells,” Journal of Biological Chemistry, vol. 280, no. 36, pp. 32018–32025, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. F. Zhang, T. Zhang, Z. H. Teng, R. Zhang, J. B. Wang, and Q. B. Mei, “Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells,” Cancer Biology and Therapy, vol. 8, no. 9, pp. 823–831, 2009. View at Google Scholar · View at Scopus
  62. T. Zhang, T. Jiang, F. Zhang et al., “Involvement of p21Waf1/Cip1 cleavage during roscovitine-induced apoptosis in non-small cell lung cancer cells,” Oncology Reports, vol. 23, no. 1, pp. 239–245, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Javelaud and F. Besançon, “Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio,” Journal of Biological Chemistry, vol. 277, no. 40, pp. 37949–37954, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Zhang, Y. Xiong, and W. G. Yarbrough, “ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways,” Cell, vol. 92, no. 6, pp. 725–734, 1998. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Pomerantz, N. Schreiber-Agus, N. J. Liégeois et al., “The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53,” Cell, vol. 92, no. 6, pp. 713–723, 1998. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Y. Pang, M. Scott, R. L. Hayward et al., “p21WAF1 is component of a positive feedback loop that maintains the p53 transcriptional program,” Cell Cycle, vol. 10, no. 6, pp. 932–950, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. X. P. Zhang, F. Liu, Z. Cheng, and W. Wang, “Cell fate decision mediated by p53 pulses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 30, pp. 12245–12250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. X. P. Zhang, F. Liu, and W. Wang, “Two-phase dynamics of p53 in the DNA damage response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 22, pp. 8990–8995, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. E. Batchelor, C. S. Mock, I. Bhan, A. Loewer, and G. Lahav, “Recurrent initiation: a mechanism for triggering p53 pulses in response to DNA damage,” Molecular Cell, vol. 30, no. 3, pp. 277–289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. X. H. Yang, T. L. Sladek, X. Liu, B. R. Butler, C. J. Froelich, and A. D. Thor, “Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis,” Cancer Research, vol. 61, no. 1, pp. 348–354, 2001. View at Google Scholar · View at Scopus
  71. D. Eriksson, P. O. Löfroth, L. Johansson, K. Riklund, and T. Stigbrand, “Apoptotic signalling in HeLa Hep2 cells following 5 Gy of cobalt-60 gamma radiation,” Anticancer Research, vol. 29, no. 11, pp. 4361–4366, 2009. View at Google Scholar · View at Scopus
  72. B. C. Kim, N. K. Han, H. O. Byun et al., “Time-dependently expressed markers and the characterization for premature senescence induced by ionizing radiation in MCF7,” Oncology Reports, vol. 24, no. 2, pp. 395–403, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. G. Gil and M. K. Kang, “Capsaicin induces apoptosis and terminal differentiation in human glioma A172 cells,” Life Sciences, vol. 82, no. 19-20, pp. 997–1003, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Banno, Y. Takuwa, Y. Akao et al., “Involvement of phospholipase D in sphingosine 1-phosphate-induced activation of phosphatidylinositol 3-kinase and Akt in Chinese hamster ovary cells overexpressing EDG3,” Journal of Biological Chemistry, vol. 276, no. 38, pp. 35622–35628, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. J. M. Albert, K. W. Kim, C. Cao, and B. Lu, “Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer,” Molecular Cancer Therapeutics, vol. 5, no. 5, pp. 1183–1189, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Y. Lim, N. Vidnovic, L. W. Ellisen, and C. O. Leong, “Mutant p53 mediates survival of breast cancer cells,” British Journal of Cancer, vol. 101, no. 9, pp. 1606–1612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Oren and V. Rotter, “Mutant p53 gain-of-function in cancer,” Cold Spring Harbor perspectives in biology, vol. 2, no. 2, Article ID a001107, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Mogi and H. Kuwano, “TP53 mutations in nonsmall cell lung cancer,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 583929, 9 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. A. K. Frank, E. C. Pietsch, P. Dumont, J. Tao, and M. E. Murphy, “Wild-type and mutant p53 proteins interact with mitochondrial caspase-3,” Cancer Biology and Therapy, vol. 11, no. 8, pp. 740–745, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. S. P. Deb, R. M. Munoz, D. R. Brown, M. A. Subler, and S. Deb, “Wild-type human p53 activates the human epidermal growth factor receptor promoter,” Oncogene, vol. 9, no. 5, pp. 1341–1349, 1994. View at Google Scholar · View at Scopus
  81. M. W. Frazier, X. He, J. Wang, Z. Gu, J. L. Cleveland, and G. P. Zambetti, “Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain,” Molecular and Cellular Biology, vol. 18, no. 7, pp. 3735–3743, 1998. View at Google Scholar · View at Scopus
  82. U. Preuss, R. Kreutzfeld, and K.-H. Scheidtmann, “Tumor-derived p53 mutant c174y is a gain-of-function mutant which activates the fos promoter and enhances colony formation,” International Journal of Cancer, vol. 88, no. 2, pp. 162–171, 2000. View at Publisher · View at Google Scholar
  83. J. Sampath, D. Sun, V. J. Kidd et al., “Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1,” Journal of Biological Chemistry, vol. 276, no. 42, pp. 39359–39367, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. W. D. Stein, “Kinetics of the multidrug transporter (P-glycoprotein) and its reversal,” Physiological Reviews, vol. 77, no. 2, pp. 545–590, 1997. View at Google Scholar · View at Scopus
  85. J. V. Thottassery, G. P. Zambettii, K. Arimori, E. G. Schuetz, and J. D. Schuetz, “p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 20, pp. 11037–11042, 1997. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Adorno, M. Cordenonsi, M. Montagner et al., “A Mutant-p53/Smad complex opposes p63 to empower TGFβ-induced metastasis,” Cell, vol. 137, no. 1, pp. 87–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Strano, E. Munarriz, M. Rossi et al., “Physical and functional interaction between p53 mutants and different isoforms of p73,” Journal of Biological Chemistry, vol. 275, no. 38, pp. 29503–29512, 2000. View at Publisher · View at Google Scholar · View at Scopus
  88. F. Talos, A. Nemajerova, E. R. Flores, O. Petrenko, and U. M. Moll, “p73 suppresses polyploidy and aneuploidy in the absence of functional p53,” Molecular Cell, vol. 27, no. 4, pp. 647–659, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. L. Hui, Y. Zheng, Y. Yan, J. Bargonetti, and D. A. Foster, “Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D,” Oncogene, vol. 25, no. 55, pp. 7305–7310, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Ventura, D. G. Kirsch, M. E. McLaughlin et al., “Restoration of p53 function leads to tumour regression in vivo,” Nature, vol. 445, no. 7128, pp. 661–665, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. H. D. Skinner, V. C. Sandulache, T. J. Ow et al., “TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence,” Clinical Cancer Research, vol. 18, no. 1, pp. 290–300, 2012. View at Publisher · View at Google Scholar
  92. R. J. Sabin and R. M. Anderson, “Cellular Senescence—its role in cancer and the response to ionizing radiation,” Genome Integrity, vol. 2, article 7, 2011. View at Google Scholar
  93. K. K. C. Tsai, J. Stuart, Y. Y. E. Chuang, J. B. Little, and Z. M. Yuan, “Low-dose radiation-induced senescent stromal fibroblasts render nearby breast cancer cells radioresistant,” Radiation Research, vol. 172, no. 3, pp. 306–313, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. R. Rajaraman, M. M. Rajaraman, S. R. Rajaraman, and D. L. Guernsey, “Neosis—a paradigm of self-renewal in cancer,” Cell Biology International, vol. 29, no. 12, pp. 1084–1097, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. D. A. Gewirtz, “Autophagy, senescence and tumor dormancy in cancer therapy,” Autophagy, vol. 5, no. 8, pp. 1232–1234, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. R. Mirzayans and D. Murray, “Pharmacological modulation of p53 function in cancer therapy,” Current Signal Transduction Therapy, vol. 3, no. 3, pp. 183–194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. D. A. Foster and L. Xu, “Phospholipase D in cell proliferation and cancer,” Molecular Cancer Research, vol. 1, no. 11, pp. 789–800, 2003. View at Google Scholar · View at Scopus
  98. Y. Zheng, V. Rodrik, A. Toschi et al., “Phospholipase D couples survival and migration signals in stress response of human cancer cells,” Journal of Biological Chemistry, vol. 281, no. 23, pp. 15862–15868, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. D. A. Foster, “Phospholipase D survival signals as a therapeutic target in cancer,” Current Signal Transduction Therapy, vol. 1, pp. 295–303, 2006. View at Google Scholar
  100. L. Hui, V. Rodrik, R. M. Pielak, S. Knirr, Y. Zheng, and D. A. Foster, “mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells,” Journal of Biological Chemistry, vol. 280, no. 43, pp. 35829–35835, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. Y. Chen, V. Rodrik, and D. A. Foster, “Alternative phospholipase D/mTOR survival signal in human breast cancer cells,” Oncogene, vol. 24, no. 4, pp. 672–679, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Fang, I. H. Park, A. L. Wu et al., “PLD1 regulates mTOR signaling and mediates Cdc42 activation of S6K1,” Current Biology, vol. 13, no. 23, pp. 2037–2044, 2003. View at Publisher · View at Google Scholar · View at Scopus
  103. L. Hui, T. Abbas, R. M. Pielak, T. Joseph, J. Bargonetti, and D. A. Foster, “Phospholipase D elevates the level of MDM2 and suppresses DNA damage-induced increases in p53,” Molecular and Cellular Biology, vol. 24, no. 13, pp. 5677–5686, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Toschi, E. Lee, S. Thompson et al., “Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells,” Cancer Letters, vol. 299, no. 1, pp. 72–79, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. N. Gadir, E. Lee, A. Garcia, A. Toschi, and D. A. Foster, “Suppression of TGF-β signaling by phospholipase D,” Cell Cycle, vol. 6, no. 22, pp. 2840–2845, 2007. View at Google Scholar · View at Scopus
  106. M. Shi, Y. Zheng, A. Garcia, L. Xu, and D. A. Foster, “Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras,” Cancer Letters, vol. 258, no. 2, pp. 268–275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Castedo, K. F. Ferri, and G. Kroemer, “Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic,” Cell Death and Differentiation, vol. 9, no. 2, pp. 99–100, 2002. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Lu, H. Wang, and G. B. Mills, “Targeting PI3K-AKT pathway for cancer therapy,” Reviews in Clinical and Experimental Hematology, vol. 7, no. 2, pp. 205–228, 2003. View at Google Scholar · View at Scopus
  109. D. Morgensztern and H. L. McLeod, “PI3K/Akt/mTOR pathway as a target for cancer therapy,” Anti-Cancer Drugs, vol. 16, no. 8, pp. 797–803, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. B. C. Valdez, D. Murray, L. Ramdas et al., “Altered gene expression in busulfan-resistant human myeloid leukemia,” Leukemia Research, vol. 32, no. 11, pp. 1684–1697, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Trepel, M. Mollapour, G. Giaccone, and L. Neckers, “Targeting the dynamic HSP90 complex in cancer,” Nature Reviews Cancer, vol. 10, no. 8, pp. 537–549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. H. Takai, Y. Xie, T. De Lange, and N. P. Pavletich, “Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes,” Genes and Development, vol. 24, no. 18, pp. 2019–2030, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. X. Yin, H. Zhang, K. Lundgren, L. Wilson, F. Burrows, and C. G. Shores, “BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy,” International Journal of Cancer, vol. 126, no. 5, pp. 1216–1225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. J. Erenpreisa, A. Ivanov, M. Cragg, G. Selivanova, and T. Illidge, “Nuclear envelope-limited chromatin sheets are part of mitotic death,” Histochemistry and Cell Biology, vol. 117, no. 3, pp. 243–255, 2002. View at Publisher · View at Google Scholar · View at Scopus
  115. F. Ianzini, E. A. Kosmacek, E. S. Nelson et al., “Activation of meiosis-specific genes is associated with depolyploidization of human tumor cells following radiation-induced mitotic catastrophe,” Cancer Research, vol. 69, no. 6, pp. 2296–2304, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. J. Erenpreisa, M. S. Cragg, K. Salmina, M. Hausmann, and H. Scherthan, “The role of meiotic cohesin REC8 in chromosome segregation in γ irradiation-induced endopolyploid tumour cells,” Experimental Cell Research, vol. 315, no. 15, pp. 2593–2603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. S. L. Warner, D. J. Bearss, H. Han, and D. D. Von Hoff, “Targeting Aurora-2 kinase in cancer,” Molecular cancer therapeutics, vol. 2, no. 6, pp. 589–595, 2003. View at Google Scholar · View at Scopus
  118. J. Erenpreisa, A. Ivanov, S. P. Wheatley et al., “Endopolyploidy in irradiated p53-deficient tumour cell lines: persistence of cell division activity in giant cells expressing Aurora-B kinase,” Cell Biology International, vol. 32, no. 9, pp. 1044–1056, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. Y. Tao, P. Zhang, F. Girdler et al., “Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152,” Oncogene, vol. 27, no. 23, pp. 3244–3255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. W. G. Kaelin and C. B. Thompson, “Q and A: cancer: clues from cell metabolism,” Nature, vol. 465, no. 7298, pp. 562–564, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. I. B. Sahra, K. Laurent, S. Giuliano et al., “Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells,” Cancer Research, vol. 70, no. 6, pp. 2465–2475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. R. L. Aft, F. W. Zhang, and D. Gius, “Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death,” British Journal of Cancer, vol. 87, no. 7, pp. 805–812, 2002. View at Publisher · View at Google Scholar · View at Scopus
  123. X. Lin, F. Zhang, C. M. Bradbury et al., “2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism,” Cancer Research, vol. 63, no. 12, pp. 3413–3417, 2003. View at Google Scholar · View at Scopus
  124. G. Maschek, N. Savaraj, W. Priebe et al., “2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo,” Cancer Research, vol. 64, no. 1, pp. 31–34, 2004. View at Publisher · View at Google Scholar · View at Scopus
  125. V. Egler, S. Korur, M. Failly et al., “Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death,” Clinical Cancer Research, vol. 14, no. 10, pp. 3132–3140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. E. D. Michelakis, L. Webster, and J. R. Mackey, “Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer,” British Journal of Cancer, vol. 99, no. 7, pp. 989–994, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. W. Cao, S. Yacoub, K. T. Shiverick et al., “Dichloroacetate (DCA) sensitizes both wild-type and over expressing bcl-2 prostate cancer cells in vitro to radiation,” Prostate, vol. 68, no. 11, pp. 1223–1231, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. J. Y. Y. Wong, G. S. Huggins, M. Debidda, N. C. Munshi, and I. De Vivo, “Dichloroacetate induces apoptosis in endometrial cancer cells,” Gynecologic Oncology, vol. 109, no. 3, pp. 394–402, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. L. Monovich, B. Mugrage, E. Quadros et al., “Optimization of halopemide for phospholipase D2 inhibition,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 8, pp. 2310–2311, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Mabuchi, D. A. Altomare, M. Cheung et al., “RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model,” Clinical Cancer Research, vol. 13, no. 14, pp. 4261–4270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. M. Wang, F. Morsbach, D. Sander et al., “EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks,” Cancer Research, vol. 71, no. 19, pp. 6261–6269, 2011. View at Publisher · View at Google Scholar